Companion Animal Diagnostics Market By Disease Type (Infectious Diseases, Chronic Diseases, Cancer & Tumor Detection, Genetic Disorders, Endocrine Disorders, and Others), By Application (Clinical Pathology, Toxicology, Bacteriology, Parasitology, Virology, Pregnancy Testing, and Others), By Technology (Immunodiagnostics, Molecular Diagnostics, Clinical Biochemistry, Hematology, Urinalysis, and Others), By Animal Type (Dogs, Cats, Horses, and Others), and By End User (Veterinary Hospitals & Clinics, Diagnostic Laboratories, Research Institutions, Point-of-Care Testing Settings, and Home Care), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape this market in the coming years?

The Companion Animal Diagnostics market accounted for USD 6.41 Billion in 2024 and USD 7.03 Billion in 2025 is expected to reach USD 17.78 Billion by 2035, growing at a CAGR of around 9.72% between 2025 and 2035. The companion animal diagnostics market targets products for testing and diagnosing pets, such as dogs, cats, and other companion animals. It has technologies and services that facilitate the detection, monitoring, and management of diseases, infections, and health issues in this type of animal. The important segments are immunodiagnostics, molecular diagnostics, clinical biochemistry, and haematology. Growth in the number of pets, increased awareness of animal health, and the development of veterinary diagnostic tools are all factors driving this market. Veterinary clinics, research labs, and animal hospitals are the main end-users.

What do industry experts say about the market trends?

"By empowering veterinary teams with valuable insights into potentially cancerous cells, we are helping to reduce waiting times and alleviate stress for pet owners facing some of the most challenging moments with their beloved pets."

• Dr. Abhay Nayak, President of Global Diagnostics at Zoetis

"Safe and effective delivery of therapeutic cargo to its target tissue at a clinically relevant dose is crucial… Nanoparticle engineering must be purpose‑driven and designed around the physical and biochemical properties of the therapeutic cargo and the disease it is designed to treat."

• Dr. John Lewis, CEO of Entos Pharmaceuticals

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the market?

Increasing pet adoption rates boost demand for veterinary diagnostics.

The increasing companion animal diagnostics market growth is dwelt upon by the increasing trend of pet adoptions. With the growing number of households having pets, particularly cats and dogs, there exists a greater demand for regular health checks and early detection of diseases, which in turn is driving the need for veterinary diagnostic equipment. The United States shows an increase in the pet population, where approximately 70 per cent of American households possess a pet, as stated by the American Pet Products Association (APPA) by 2023. Further, the U.S. Centers for Disease Control and Prevention (CDC) highlight the significance of veterinary diagnostics in averting zoonotic diseases and improving the health of pets and people.

A typical pet owner is more open to making investments in advanced diagnostics services, such as blood tests, imaging, explanation, and molecular diagnostics, in alignment with a growing realisation that pets are regarded as family members. Another factor that helps the market to fulfil its growth is the increased visits to veterinary care, with the increased awareness of pet health due to the reports made by the USDA. It is a collection of all those pharmaceutical conditions based on the expanding population of pets and the increased pressures of health awareness and visibility, accompanied by better access to veterinary services, that promotes the growing demand in companion animal diagnostics.

Technological advancements enhance accuracy of diagnostic equipment rapidly.

The companion animal diagnostics market is driven by the rising number of pet keepers globally, particularly in cities, where there has been an increased need for sophisticated veterinary services, such as precise diagnostic tools. The invention of technology machines like AI, point-of-care testing, and molecular diagnosis has enhanced the rate and quality of disease diagnosis so that veterinarians are increasingly using them. The increasing participation of pet owners in preventive medicine leads to an increased demand for diagnostic procedures.

The American Veterinary Medical Association (AVMA) reported that pet ownership in the United States in 2021 became 70% of the households, indicating an increase in investment in pet health. In addition, the National Institutes of Health (NIH) underline the fact that animal welfare issues are also improved by the use of better diagnostic procedures, which can be used to address treatment costs. The listed factors work together to promote innovation and an increase in the area of companion animal diagnostics.

Regulatory challenges slow new product approvals across global markets.

The regulatory procedures have high complexity, which makes the process long in most parts of the world, limiting the Companion Animal Diagnostics Market. The Centre for Veterinary Medicine of the FDA in the U.S. demands a lot of clinical information and tests, and it usually takes more than a year to be approved. Further approval complexity is the strict conformity checking and permanent surveillance in the post-market of the European Union In Vitro Diagnostic Regulation (IVDR) that came into force in 2022.

University of California, Davis research finds that these strict rules raise the cost of development and prolong the schedules, restricting quick innovation. New markets such as India and Brazil have new local trial requirements in the form of regulatory institutions such as CDSCO and ANVISA, which further delay the process. Such regional and local variation in regulation poses a serious obstacle, as new diagnostic solutions take much time to reach the market and companion pets across the world. This makes it difficult to expand the market since it delays the entry of new products and makes it more expensive to operate the business.

Telemedicine integration creates growth potential in remote animal care.

Automation of telemedicine in veterinary care is transforming the companion animal diagnostics market by increasing access to timely and specialised veterinary care in remote and rural services and distant localities. With this technology, pet owners can gain access to expert consultation, diagnostic interpretation, and follow-up treatment regardless of their geographical location, hence increasing market growth. The American Veterinary Medical Association (AVMA) indicates that more than 67 per cent of American households have a pet, and the demand for veterinary services is on the rise.

The U.S. Department of Agriculture (USDA) points out the insufficient level of veterinary professionals in rural communities, as it is an important area where telemedicine could be used as its solution. Furthermore, the CDC mandates that zoonotic disease diagnosis in pets must be done accurately and promptly. It is crucial to emphasise that, in this sense, the increased availability of diagnostic tools through telemedicine is an extension of the concept of a better diagnosis. All these aspects give further weight to the argument that there is a great potential for an increase in companion animal diagnostics promoted by the benefits that telemedicine offers to the quality and convenience of care.

Strategic partnerships expand reach of diagnostics to underserved areas.

The strategic alliances provide an invaluable chance of bringing companion animal diagnostics to underserved regions that do not have access to veterinary care. The USDA considers that almost 60% of rural American households have pets, and there is an unequal distribution of veterinary diagnostic laboratories in such places compared to in urban centres. The result of such a gap is late diagnoses and treatment. The outreach interventions can be enhanced through the collaboration of local clinics and veterinary institutions with government health departments, sending out mobile diagnostic units, and using telehealth services.

The National Animal Health Monitoring System (NAHMS) notes that when diseases affecting companion animals are diagnosed early, then their costs of treatment are minimised and the outcomes achieved, which is particularly important to underserved communities. Further, there are universities like the University of California, Davis, which focus more on the training process involving the assimilation of the rural practitioners into the diagnostic labs to reduce skills and access deficiencies. Strategic partnerships can greatly enhance animal health equity despite the fact that advanced tests are being brought nearer to pet lovers in far-flung areas. This will eventually lead to better management of diseases and better animal welfare in the companion animal diagnostics market.

What are the key market segments in the industry?

Based on the Disease type, the Companion Animal Diagnostics market is classified into Infectious Diseases, Chronic Diseases, Cancer & Tumor Detection, Genetic Disorders, Endocrine Disorders, and Others. The infectious disease segment is one of the most prominent in the companion-animal diagnostic market. This dominance is mainly attributed to a large number of infectious conditions, such as parvovirus, distemper, and respiratory infection, in the pet population that require prompt and accurate diagnosis to prevent outbreaks and treatment.

The rapid detection and monitoring of infectious diseases in the health of animals are important for the prevention of disease transmission, elevating the importance of this segment. Further, an upward trend of awareness among pet parents and veterinarians regarding the prevention and control of diseases has added to the demand for the diagnostics of infectious diseases in companion animals.

Based on the application, the Companion Animal Diagnostics market is classified into Clinical Pathology, Toxicology, Bacteriology, Parasitology, Virology, Pregnancy Testing, and Others. The clinical pathology segment represents the largest share of the Companion Animal Diagnostics market. A wide range of necessary diagnostic tests are performed under clinical pathology tests, such as blood tests, haematology, and biochemistry, which serve as avenues for measuring the overall health status of the pet.

Clinical pathology gives diagnostic clues for a variety of diseases, assesses responses to therapy, and provides management for chronic diseases, and it is indispensable to the veterinarian. Because of its wide applicability and routine use in veterinary practice, this market is the leading shareholder within the industry, with an increasing demand for comprehensive health assessment in companion animals.

Which regions are leading the market, and why?

The North American Companion Animal Diagnostics Market is growing rapidly, with a growing number of pet owners and awareness of animal diseases. Modern veterinary diagnostic solutions are gaining popularity throughout the area with the available strong veterinary infrastructure and the rise in expenditure in pet healthcare.

Superior representation of the major diagnostic firms and continuous advancement of point-of-care testing and molecular diagnostics are advantages to the market. What also adds to the demand is the fact that pet owners are ready to spend money on preventative care and early detection of diseases. Nevertheless, regulatory policies and the expenses incurred in complex diagnostic devices can be a setback. North America is one of the key markets for companion animal diagnostics, and there are good chances to develop it with the help of technology integration and the increase in the number of pets adopted.

The Asia Pacific companion animal diagnostics market is mushrooming, owing to the growing number of pet owners and pet health awareness. Urbanisation and the emergence of the middle class have contributed to the increase in disposable income, which has given a pet owner an opportunity to spend more to access high-technology diagnostic services. Due to the increasing demand for high-percentage detection and cure of diseases, the veterinary clinics and hospitals are turning to more advanced medical diagnostic equipment. Moreover, point-of-care tests and molecular diagnostics technology solutions are weaving their way into the area as well.

The market can also be expanded by government programmes advocating for the well-being of animals. Nevertheless, such barriers as a low level of awareness in rural regions and expensive medical services involving high-tech diagnostics persist. Overall, the area has real prospects as market participants, as the activities around pet care and spending on the well-being of companion animals have promoted several changes.

What does the competitive landscape of the market look like?

The companion animal diagnostics market is highly competitive due to ever-improving technology and escalating demand for pet healthcare services in the world. The existence of major participants with large numbers of products and distribution channels, such as IDEXX Laboratories, Zoetis Inc., and Mars, Inc., characterises the market.

The recent move involves strategic acquisitions and alliances to increase the capabilities of diagnostic offerings. Mars, Inc. boosted itself by acquiring Heska Corporation to boost point-of-care diagnostic solutions. Moreover, other firms, including Thermo Fisher Scientific and Neogen Corporation, are investing in new technology to ensure that molecular and immunoassay kits are more precise and faster to arrive at a diagnosis.

Asian companies such as Bionote Inc. and Mindray Medical are emerging in the market in Asia, especially with cost-effective and advanced diagnostic devices, which has led to the dynamic nature of the market. Altogether, the competitive differentiation depends on the innovations, geographic extension, and customised solutions to fulfil the health-related needs of the companion animals.

Companion Animal Diagnostics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the industry?

• In May 2025, Radimal entered into an exclusive partnership with Petfolk. The deal aimed to provide teleradiology support across Petfolk’s veterinary network. This partnership improved access to specialist imaging interpretation. It helped enhance veterinary diagnostic services.
• In February 2025, IDEXX stock surged by about 10% after strong Q4 earnings. This growth was driven by a 6% rise in recurring revenue from the Companion Animal Group (CAG) diagnostics. CEO Jay Mazelsky announced the upcoming launch of a severe cancer screening test for canine lymphoma called "Cancer Dx." The test was expected to be available late next month in the U.S. and Canada.

Report Coverage:

By Disease Type

• Infectious Diseases
• Chronic Diseases
• Cancer & Tumor Detection
• Genetic Disorders
• Endocrine Disorders
• Others

By Application

• Clinical Pathology
• Toxicology
• Bacteriology
• Parasitology
• Virology
• Pregnancy Testing
• Others

By Technology

• Immunodiagnostics
• Molecular Diagnostics
• Clinical Biochemistry
• Hematology
• Urinalysis
• Others

By Animal Type

• Dogs
• Cats
• Horses
• Others

By End User

• Veterinary Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutions
• Point-of-Care Testing Settings
• Home Care

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• IDEXX Laboratories, Inc.
• Zoetis Inc.
• Thermo Fisher Scientific Inc.
• Mars, Inc.
• Neogen Corporation
• Virbac S.A.
• bioMérieux S.A.
• QIAGEN N.V.
• Aggrolabo S.p.A.
• Randox Laboratories Ltd.
• IDvet
• Fujifilm Holdings Corporation
• Mindray Medical International Ltd.
• Bionote Inc.
• Skyla Corporation

Frequently Asked Questions (FAQs)